Navigating the Future of Pricing with AI: Pricing Co-Pilot

In the complex and fast-evolving landscape of global markets, the strategic importance of pricing can hardly be overstated. It’s the linchpin that not only affects revenue and margins but also determines market competitiveness.

This is where Artificial Intelligence (AI) steps in, revolutionising the way industries approach pricing strategies. In particular, the implementation of AI in tender and RFP (Request for Proposal) pricing across Italy, Spain, France, the Nordics, and other EU & ME markets has been nothing short of transformative.

The AI-Driven Pricing Revolution

AI technology has opened new avenues for analysing historical data, recognising patterns of wins and losses, and applying these insights to future tenders and RFPs. This analytical prowess has empowered businesses with predictions and scenarios rooted in real-life outcomes, leading to substantial revenue growth — ranging from 12% to 25% — and enhanced margins by 17% to 25% across diverse markets and assets.

Our Three-Phased Approach to Pricing

Our journey towards pricing is meticulously structured into three phases, each designed to build upon the insights and foundations laid in the preceding steps.

Phase 1: Data Discovery, Cleansing, and Enrichment

The first step in the process is to meticulously curate and enhance the dataset, ensuring its integrity and richness. This involves a thorough examination of the data to identify any inconsistencies, errors, or missing information that could potentially undermine the accuracy of the predictive models. Once these issues are detected, the data undergoes a rigorous cleansing process to correct the invalid entries and ensure the dataset’s overall quality.

However, the preparation phase goes beyond mere data cleaning. To truly unlock the potential of the predictive models, it is essential to enrich the dataset with valuable market insights. This enrichment process involves integrating relevant external data sources, such as industry trends, competitive intelligence, and regulatory information, to provide a more comprehensive and contextual understanding of the market dynamics.

By combining the internal data with these external insights, the dataset becomes a powerful asset that can drive more accurate and actionable predictions. This solid foundation of clean, enriched data sets the stage for the development of robust and reliable predictive models in the subsequent phases of the project.

Phase 2: Model Building

In this phase, the focus is on developing sophisticated predictive models that incorporate a vast array of variables. These models are designed to tackle complex challenges, such as forecasting prices at the molecular level and identifying the most likely winning bids for individual stock-keeping units (SKUs).

The algorithms take into account a wide range of factors that influence the pricing of drugs or medical products throughout their entire lifecycle, from initial launch to post-patent expiry scenarios. By considering the impact of various market dynamics, regulatory changes, and competitive landscapes, these models provide valuable insights into pricing strategies and help organisations navigate the complexities of the pharmaceutical and healthcare industries. The ultimate goal is to empower local teams with data-driven recommendations that optimise revenue, maximise profitability, and ensure sustainable growth in an increasingly competitive market.

Phase 3: Iterative optimisation through A/B testing and reinforcement learning

In the final phase of the project, a two-pronged approach will be used to refine and validate the effectiveness of our pricing pilot. First, extensive A/B testing will be conducted, comparing the performance of our AI-driven pricing strategies with traditional methods. This rigorous benchmarking process will allow us to quantify the concrete improvements and added value brought by the new solution. By measuring key metrics such as revenue growth, margin expansion, and market share gains, the model simulates real-world scenarios.

However, for a continuous learning process, we harness the power of reinforcement learning to create a self-optimising feedback loop. Because Pricing Co-Pilot is deployed under real market conditions, it actively learns from the results of its decisions. By analysing real-world results, the machine learning algorithms identify patterns, correlations, and causal relationships between different factors and their impact on pricing effectiveness. This ongoing learning process allows the models to adapt and refine their predictions over time, becoming increasingly accurate and responsive to changing market dynamics.

One of the key benefits of this iterative optimisation approach is the ability to simulate a variety of scenarios. Leveraging the advanced models, teams can explore different pricing strategies, campaigns, and competitive responses in a virtual environment. This allows them to evaluate the potential outcomes and risks associated with each scenario and empowers them to make informed decisions based on data-driven insights.

By combining A/B testing and reinforcement learning, the Pricing Co-Pilot aims to achieve continuous evolution and adaptation to the ever-changing landscape of the pharmaceutical and medical device industries. This phase serves as the foundation for the project, delivering a robust, reliable, and continuously improved pricing solution that drives sustainable growth and profitability.

The Vamstar Difference

The drive for greater commercial efficiency has become increasingly urgent against a backdrop of inflation, shortages, and the shift towards value-based healthcare. Vamstar distinguishes itself by leveraging AI to orchestrate, analyse, and provide intelligence on MedTech and Pharmaceutical data. This approach not only enhances market visibility but also optimises pricing strategies, thereby simplifying and automating commercial workflows to achieve sales excellence.

The Impact

Adopting AI in pricing does more than just improve financial metrics; it represents a paradigm shift in how businesses approach the market. By providing a granular view of demand and supply dynamics, and facilitating informed decision-making, AI technologies like those offered by Pricing Co-Pilot are setting new standards for efficiency and competitiveness in the healthcare sector.

Conclusion

The integration of AI into pricing strategies marks a significant leap forward for industries striving to navigate the complexities of modern markets. With its proven track record of enhancing revenues and margins, AI offers a promising path to not just survive but thrive in the competitive landscape. As we continue to explore and refine these technologies, the possibilities for innovation and improvement in pricing strategies are boundless.